Active and Passive Vaccination against Hantavirus Pulmonary Syndrome with Andes Virus M Genome Segment-Based DNA Vaccine

Hantavirus pulmonary syndrome (HPS) is a rapidly progressing human disease with one of the highest case fatality rates (30 to 50%) of any acute viral disease known. There are no vaccines, effective antiviral drugs, or immunologics to prevent or treat HPS. In an attempt to develop HPS medical counter...

Full description

Saved in:
Bibliographic Details
Main Authors: Custer, D. M., Thompson, E., Schmaljohn, C. S., Ksiazek, T. G., Hooper, J. W.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2003
Subjects:
Vaccines and Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC224585/
https://ncbi.nlm.nih.gov/pubmed/12941899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.77.18.9894-9905.2003
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items